Evidence map›Paper›PMID 42136978›Full record

ArticleAdvances in laboratory medicine2026

Anti-GBM pulmonary-renal syndrome: when the laboratory makes the difference.

Carmen Frías Ruiz, María D Martín Martínez

Abstract readCase Reports
In one paragraph

Article in Advances in laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carmen Frías RuizServicio de Análisis Clínicos, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.ORCID https://orcid.org/0009-0008-9322-2804
María D Martín MartínezServicio de Análisis Clínicos, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Pulmonary-renal syndrome (PRS) is a serious condition characterized by concurrent alveolar hemorrhage and rapidly progressive glomerulonephritis. One of the potential causes of PRS is the presence of anti-glomerular basement membrane (anti-GBM) antibodies, which may induce Goodpasture syndrome, a rare, albeit life-threatening, condition associated with a high mortality. Case presentation: We report the case of a 31 year-old male patient with Huntington's disease who presented with dyspnea, a dry cough, and asthenia. Urgent laboratory tests demonstrated severe anemia, acute kidney failure, and additional laboratory abnormalities consistent with vasculitis. Chest CT scan revealed diffuse alveolar hemorrhage. The autoimmune panel was anti-GBM positive, thereby leading to diagnosis of Goodpasture syndrome. Conclusions: Goodpasture syndrome is a form of pulmonary-renal syndrome that requires prompt diagnosis and intensive immunosuppressive therapy. Patients may follow a severe course and progress into end-stage renal disease. Early detection of anti-GBM antibodies is essential for diagnosis. The clinical laboratory plays a major role in supporting therapeutic decision-making and treatment response monitoring.

Indexed as

anti-GBM diseaseanti-glomerular basement membrane (anti-GBM)goodpasture syndrome

Identifiers

PMID42136978
PMCPMC13169443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.